Thus, Silibinin offers a potential therapeutic effect against AD by mitigating Aβ1–42-induced cognitive deficits and neuronal damage, partly through the modulation of estrogen receptors and related signaling pathways [58]. Here, ESR1 is linked to Alzheimer disease.